North Chicago drug giant AbbVie is reportedly closing in on a deal to buy Apogee Therapeutics, a clinical-stage immunology company, in a transaction that would value the smaller biotech at roughly $11 billion. The proposed move would hand AbbVie control of Apogee's lead IL-13 antibody program, a late-stage candidate that analysts say could shake up treatment for atopic dermatitis and other inflammatory conditions.
The talks were first detailed by Crain's Chicago Business, which reported that AbbVie has put an all-cash offer on the table. The outlet cited people familiar with the negotiations, and at the time of that report, neither AbbVie nor Apogee had issued a public statement confirming the potential deal.
What Apogee Brings
Apogee drew heightened interest in May, when it announced that its APEX Phase 2 Part B trial of zumilokibart met all primary and secondary endpoints. The company reported that the mid-dose group achieved a 65.9% EASI-75 response at 16 weeks, data that quickly put the asset on the radar of larger drugmakers. Those efficacy results, along with a $1.3 billion strategic financing collaboration with Blackstone Life Sciences to support Phase 3 development, were laid out in a May press release from Apogee Therapeutics.
Why AbbVie Would Pay Up
AbbVie has been leaning harder on newer immunology drugs as Humira encounters mounting biosimilar competition, and its most recent quarter showed that immunology still accounts for the bulk of the company's revenue. Adding Apogee would slot in a late-stage IL-13 asset that could complement Skyrizi and Rinvoq and help keep AbbVie's immunology engine running, according to figures in AbbVie's investor materials. Those portfolio numbers were broken out in an April earnings release from AbbVie.
Deal Math And Market Reaction
Reports peg the potential price tag at about $10.9 billion, a rich premium to Apogee's recent share price that sent the stock sharply higher in early trading, according to market coverage. Commentators have linked the aggressive valuation to May's efficacy readout and the sizable Blackstone financing package, which together signaled strong commercial potential. MarketBeat collected analyst chatter and detailed the trading surge.
If AbbVie and Apogee ink a definitive agreement, the deal would still have to clear customary closing conditions and win regulatory approvals. Apogee's investor disclosures state that the Blackstone financing includes change-of-control provisions that could shape the timing and economics of any takeover. Representatives for both companies did not immediately respond to requests for comment.
